As genetic screening technology grows more compact and simple to implement, test kits for laboratory and point of care diagnosis for a wide range of applications are entering the international marketplace. The uses of these kits range from cancer detection and staging to human growth factor analysis to diabetes typing. Some of these kits have been approved for use in the U.S. and inevitably many more will become available in the future.
PerkinElmer Life and Analytical Sciences, Inc., Boston, Mass., produces dozens of genetic screening tests, most of which are presently marketed only outside the U.S. A few of these products, however, are approved for use in this country. For example, PerkinElmers Cerebrospinal Fluid Kit provides a sensitive and rapid method of separating and detecting oligoclonal immunoglobulin bands in unconcentrated cerebrospinal fluid using isoelectric focusing. The presence or absence of these bands is important as supporting evidence for the diagnosis of central nervous system (CNS) disorders. This kit is useful in the diagnosis of multiple sclerosis and other CNS diseases. Each kit contains 5 gels, anolyte and catholyte solutions, ammonium nitrate, silver nitrate, tungstosilicic acid, formaldehyde, precut wicks, gel blotting papers, sample blotting strips, and templates. This assay is available in either 30 or 50 kit packages.
PerkinElmers DELFIA and AutoDELFIA kits for the quantitative determination of human estradiol in serum are also available in the U.S. These are highly sensitive assays that offer convenience and speed for in vitro fertilization treatment, and enable diagnosis of post-menopausal status. All requests for estradiol can be accommodated with one assay and an IVF protocol is available to ensure rapid turnaround of results. These solid-phase